Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BEAM |
---|---|---|
09:32 ET | 8991 | 23.17 |
09:34 ET | 1695 | 23.25 |
09:36 ET | 2329 | 23.34 |
09:38 ET | 1200 | 23.3 |
09:41 ET | 573 | 23.31 |
09:43 ET | 100 | 23.32 |
09:45 ET | 225 | 23.198 |
09:48 ET | 394 | 23.235 |
09:50 ET | 3259 | 23.25 |
09:52 ET | 800 | 23.25 |
09:56 ET | 300 | 23.31 |
09:57 ET | 1300 | 23.255 |
09:59 ET | 900 | 23.255 |
10:01 ET | 4386 | 23.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Beam Therapeutics Inc | 1.9B | -13.2x | --- |
Galapagos NV | 1.9B | 53.4x | --- |
Genmab A/S | 15.6B | 18.9x | +22.71% |
Catalyst Pharmaceuticals Inc | 2.4B | 37.4x | --- |
Maravai LifeSciences Holdings Inc | 2.0B | -7.8x | --- |
BioCryst Pharmaceuticals Inc | 1.5B | -10.1x | --- |
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
---|---|
Revenue (TTM) | $352.6M |
Shares Outstanding | 82.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.85 |
EPS | $-1.76 |
Book Value | $12.02 |
P/E Ratio | -13.2x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.